STING agonists are currently being evaluated in clinical trials (NCT02675439, NCT03937141) for cancer treatment, since the cGAS–STING axis emerged as essential to activate antitumor effector T cells in response to genotoxic stresses and immune-based therapies [17,18,19,20,21,22]. The gene discussed is STING1; the disease is cancer.